Repositioning Microtubule Stabilizing Drugs for Brain Disorders

Artemis Varidaki, Ye Hong and Eleanor T. Coffey*

Turku Centre for Biotechnology, Åbo Akademi University and University of Turku, Biocity, Tykistokatu, Turku, Finland

Microtubule stabilizing agents are among the most clinically useful chemotherapeutic drugs. Mostly, they act to stabilize microtubules and inhibit cell division. While not without side effects, new generations of these compounds display improved pharmacokinetic properties and brain penetrance. Neurological disorders are intrinsically associated with microtubule defects, and efforts to reposition microtubule-targeting chemotherapeutic agents for treatment of neurodegenerative and psychiatric illnesses are underway. Here we catalog microtubule regulators that are associated with Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis, schizophrenia and mood disorders. We outline the classes of microtubule stabilizing agents used for cancer treatment, their brain penetrance properties and neuropathy side effects, and describe efforts to apply these agents for treatment of brain disorders. Finally, we summarize the current state of clinical trials for microtubule stabilizing agents under evaluation for central nervous system disorders.

Keywords: microtubules, cytoskeleton, kinase, psychiatric disorder, schizophrenia, depression, neurodegenerative disease, cancer

Neurons are highly specialized cells that show unique dependencies on microtubules

Neuronal cells are highly compartmentalized consisting of a soma, axon(s), dendrites, and synapses. These compartments develop because of particular cytoskeletal arrangements that are specific to neurons (Witte and Bradke, 2008). Axons convey long distance electrical signals leading to neurotransmitter release from nerve terminal active zones. They vary in length from around 1 mm in hippocampal neurons, to 1 m in certain motor neurons; posing a long distance transport challenge. To overcome this, neurons develop a highly specialized transport system constructed from microtubule polymers and microtubule binding proteins (Matamoros and Baas, 2016; Zahavi et al., 2017). Polymers form from alpha/beta tubulin dimers for which several isoforms exist in brain (Cleveland et al., 1978; Gozes and Litthauer, 1978). Microtubules display alternating shrinkage and growth controlled by GTP hydrolysis, a process that is inhibited by binding of microtubule-associated protein (MAPs). Several classes of MAPs exist in the nervous system that confer rigidity to microtubule tracks and enable motor proteins to travel long distances carrying cargo (e.g., mitochondria, proteins, and RNA granules) from soma to dendrites, synapses and axonal terminals. Microtubules themselves undergo post-translational modifications, phosphorylation, acetylation, tyrosination, and polyglutamylation (Marchisella et al., 2016), that mark them for binding by specific proteins, in particular motor proteins (Verhey and Gaertig, 2007). Cargo transport in neurons is directional, kinesin motors transport cargo toward axon terminals (anterograde) and dynein motors carry cargo away from axon tips (retrograde) (Vale, 2003).
Microtubules play fundamental roles in diverse cellular processes, including polarization, migration, cell division, and perhaps most crucially in mature neurons, microtubules facilitate cargo transport. It is therefore not surprising that a large number of genetic variants have been identified that influence healthy functioning of the microtubule cytoskeleton, beyond tubulin isoforms themselves or MAPs. Such microtubule regulators include protein kinases and other post-translational modifying enzymes and signaling proteins, motor proteins, adaptors, ligases, chaperones, scaffolds, and adhesion molecules. Genetic disruption of many of these regulators is associated with pathological disturbance of the neuronal cytoskeleton (summarized in Table 1).

Neurons are particularly susceptible to microtubule defects and deregulation of the microtubule cytoskeleton occurs in a range of neurodegenerative disorders (Matamoros and Baas, 2016). These include Parkinson’s and Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and Parkinsonian disorders e.g., progressive supranuclear palsy, all of which have been linked to polymorphisms in the microtubule stabilizing protein Tau (MAPT) (Zhang et al., 2017). Neurofibrillary lesions consisting of insoluble Tau (MAPT) filaments form in brains from patients with Alzheimer’s, Parkinson’s, Pick’s disease and in Purkinje cell degeneration and ALS (Goedert et al., 2017). Not only neurodegenerative diseases, but also migration disorders can result from microtubule anomalies. Lissencephaly is one such condition which is linked to genetic aberrations in genes encoding tubulin isoforms and tubulin stabilizing proteins, for example doublecortin (Liu, 2011). It results in cortical lamination defects that produce severe intellectual disability and reduced lifespan (Reiner and Sapir, 2013). Crucially also, genetic mutations in tubulins, MAPs, microtubule regulatory proteins and microtubule motor proteins are among the risk genes for schizophrenia spectrum disorders and depression (Marchisella et al., 2016).

**BRAIN DISORDERS ARE ENRICHED FOR DEFECTS IN GENES ENCODING MICROTUBULE REGULATORS**

To realize the extent to which microtubule dysregulation is involved in brain disorders, we utilized. Thomson Reuter's MetaCore gene enrichment tool and database that sources disease associations from clinical studies and animal disease models. MetaCore classification of microtubule regulators incorporates a broad range of genes that regulate or associate with microtubules, including non-classical regulators. Two such examples are BRC1, which regulates γ-tubulin, leading to impaired microtubule nucleation (Sankaran et al., 2007), and KIF26B which lacks the ATPase activity of its motor homologs, but associates with microtubules. Searching for the term “microtubule regulation and disease,” several brain diseases emerged with significant enrichment for genes in this category.

ALS showed the highest enrichment for “microtubule regulation and disease” genes, among brain diseases. ALS-associated genes encoded five protein kinases, three microtubule motors and Tau (MAPT) as well as chaperones and scaffolds. The diseases that showed the next highest level of enrichment were schizophrenia and psychotic disorders. Schizophrenia is a heritable disorder where several gene variants combine to confer disease risk. It is interesting that schizophrenia showed the highest percent of genetic associations for tubulin isoforms and MAPs, among brain diseases, while protein kinases and other signaling proteins were also highly represented. Of particular interest, sixty percent of the “microtubule regulation and disease” genes that associated with bipolar disorder corresponded with schizophrenia spectrum disorders, suggesting that these genes may contribute to overlapping negative symptoms. Finally, the disease that associated with the largest overall number of known “microtubule regulation and disease” genes was Alzheimer’s disease, which was associated with 82 genes fitting this search term.

It is worth noting that the genetic landscape of Alzheimer’s and Parkinson’s disease have not been studied as extensively by GWAS as has the classical polygenic disorder, schizophrenia. Instead, Alzheimer’s investigations have focused more on a small number of high penetrance gene mutations that cause autosomal dominant Alzheimer’s disease. Yet as this accounts for under 10% of cases, disease-spectrum approaches to study Alzheimer’s are relevant, and improved technologies increase feasibility (Van Cauwenbergh et al., 2016). Nonetheless, with current information and straightforward bioinformatics analysis, a higher proportional association of microtubule proteins and MAPs is found for psychiatric disorders (schizophrenia and bipolar, 17 and 7.4% respectively) than for Alzheimer’s disease (2.4%). Overall, this enrichment for microtubule regulator genes among major brain disorders emphasizes the importance of proper microtubule regulation for brain health.

**MICROTUBULE STABILIZING AGENTS IN THE CLINICS**

The realization that microtubule dysfunction is associated with neuronal disorders, has fuelled efforts to reapply knowledge gained from cancer therapies, where tubulin polymerisation inhibitors have been used for over 50 years. These drugs are under investigation for the treatment of neurodegenerative and psychiatric disorders, as can be seen from the flurry of clinical trial activity in this area (Figure 1; Table 2). The story begins with taxol, one of the earliest recognized microtubule stabilizing agents.

**PACLITAXEL (TAXOL)**

Paclitaxel commonly known as “Taxol” is a member of the taxane family. It is a natural compound, antineoplastic drug that was isolated from the bark of the Pacific yew tree (Taxus brevifolia) by the botanist Arthur Barclay in 1962, as part of a National Cancer Institute plant-screening program carried out in collaboration with the U.S. Department of Agriculture from
Using the MetaCore database, we performed a disease enrichment analysis for the term “microtubule regulation and disease”. Enrichment scores (p-value) and false discovery rates (FDR) are shown for nervous system disorders. Colors mark gene groups as follows: tubulin isoforms and microtubule binding proteins (blue), other signaling proteins (red), microtubule motor proteins (green), and protein kinases (purple), other signaling proteins (green). The literature references for these associations are as follows; for Amyotrophic lateral sclerosis: (Krüger et al., 1998; Ito et al., 2003; Jordan–Sciutto et al., 2003; Beyer et al., 2004; Kwok et al., 2005; Stichel et al., 2005; Gencer et al., 2012) and bipolar and mood disorders (Wang and Friedman, 1996; Lesort et al., 1999; Beasley et al., 2002; Torrey et al., 2005; Yuan et al., 2010; Bernard et al., 2011).

### TABLE 1 | Disease enrichment for “microtubule regulation and disease”.

| Diseases                  | P-value       | FDR            | Gene Names                                                                 |
|---------------------------|---------------|----------------|-----------------------------------------------------------------------------|
| Amyotrophic Lateral Sclerosis | 6.63E-14      | 1.88E-12       | DCTN1, GSK3B, PRK2C, KIF3A, MAPK14, DISC1, RNF19A, KIFAP3, APP, GRD2, TRIM68, PRKCA, AKT1, MAPT, ALS2, S100A10, HSPB1, APEX1, CYFIP1, YWHAE |
| Schizophrenia             | 1.61E-12      | 3.17E-11       | ATR4, GAPDH, GSK3B, SPTAN1, TUBB, MAP2K1, SLC1A4                             |
| Schizophrenia Spectrum    | 2.47E-12      | 4.75E-11       | BCL2L1, DISC1, CTNNB1, GNA1, PKp4, APP, CH1P1, YWHA, TUBB2B, MAP1A, DNM1, MED12, SLC9A3, GRD2, PRKCA, DYSPL2, GNA3, AKT1, KIF2A, PLA2G6, NDE1, HTT, TUBA1A, MAP6, SMC3, MAP1B, TAPP3, DAB1, SORBS1, CALM1, MAPK1, PDE4D, KIF1A, FEZ1, CNT, TUBA5, PLA2G3, PRKCA, S100A10, FGR, TFAP2A, BIRC2, PCMI, CTT3, DVL1, CTT2, HSPB1, HDAC2, MAPK3, NDEL1, GNA2, MDH1, APC, ATPT6V0D1, ERC2C, MAP2, ATM, RPS6KIA2, SPFA1, TBC8, SNAP29, MAP2K2, AH1, TCP1 |
| Other Psychotic Disorders |               |                |                                                                            |
| Alzheimer’s Disease, Early Onset | 4.44E-11      | 7.40E-10       | APP, MAP2T, PSEN2, ABCA2, PSEN1                                             |
| Alzheimer’s Disease       | 1.22E-09      | 1.77E-08       | ATR4, GAPDH, CRYAB, GSK3B, APPB2P, CASP8, MAP2K1, TIAM1, FNTA, HSPA2, DISC1, PRKAR2A, CTNNB1, SIRT2, APP, SLC8A1, DAAM1, SVL, CSNK1A1, GRD2, PRKCA, AKIN1, FLOT1, KLK6, KIF1, CSNK1D, AKT1, MAP6K1, MAP2K2, MAPT, ACTR1A, TRC8P, BRCA1, LCK, HTT, KIF26B, RELB, ZFYVE19, POLB, NEDD9, MAPK1, BCASS, PGOIF5, SNGC, SNX10, DNM1, KIF13B, ABLB4, PLA2G3, KLC1, NME1, HOOK3, PRKAR2B, HSPA1A, NDRG2, F11R, PDE4B, DNM2, SLC9A4, PRKACA, LPC1, APO2D, DYN1C1, S100A10, FGR, MYH1, DVL1, PSEN2, MAPK3, CLI5C, APEX1, GNA1, ABCA2, MAPK1, PSEN1, KL1, STNN1, CEP164, KCNAB2, TAPMAP2K2, CDK1, DAXX, BID2 |
| Bipolar Disorder          | 4.40E-09      | 7.48E-09       | ATR4, GAPDH, GSK3B, PRK2C, MAP2K1, SLC1A4, BCL2L1, PCNT, DISC1, CTNNB1, GNA1, SIRT2, CSNK1A1, MED12, GRD2, PRKCA, CRHBP, CSNK1D, DYSPL2, VAPA, GNAE, MAP2K, TIMELESS, NDE1, MARCKS, SMC3, MAP1B, DAB1, MAPK1, PDE4D, PLA2G3, NRS1C, HSP1A1, SYNJ1, DNM1, SLC9A4, PRKACA, PAPAH1B1, S100A10, TFAP2A, DVL1, NEIL1, HSPA1, HDAC2, MAPK3, NDEL1, GNA2, MAP2, RPS6KIA2, TRIM55, ATFS, GJA1, MAP2K2, OR2A4 |
| Alzheimer’s Disease, Late Onset | 9.42E-06      | 7.12E-05       | GSK3B, FNTA, DISC1, APP, SLC8A1, DAAM1, SVL, GRD2, PRKCA, AXIN1, MAP1T, ACTR1A, TRC8P, KIF26B, RELB, NEDD9, BCASS, SNX10, KIF13B, ABLB4, HOOK3, PDE4B, DYN1C1, MYH1, PSEN2, CLI5C, PSEN1, KCNAB2, BID2 |
| Intellectual Disability   | 1.39E-05      | 0.000102       | PCNA, DOX, CENPJ, MAP2K1, APP, CSNK1A1, MED12, CDC42, GRD2, BBS4, CSNK1D, DYSPL2, HINT1, SMC3, OFD1, SPAST, PDE4D, FGF13, PLA2G3, NME1, POBP1, HDAC4, PDE4B, STK26, S100A10, RAB3D, CCT2, HDAC2, MBD1, RPS6KIA2, BBS2, PSEN1, STMN1, UPF3B, MAP2K2, STIL, NDN, TCP1, CC2D1A, YWHAE |
| Parkinsonian Disorders     | 0.000161      | 0.000984       | GSK3B, BCL2L1, RNF19A, APP, CSNK1A1, ROCK1, GRD2, CSNK1D, RB1, MAP1T, ATF4, NEDD9, SNGC, KLC1, HSPA1A, SLC6A4, S100A10, APEX1, KLC3, ERC2C, PSEN1, YWHAE |
| Schizophrenia, Disorganized | 0.000402      | 0.000275       | GSK3B                                                                 |
| Schizophrenia, Paranoid   | 0.00781       | 0.032133       | GSK3B, SLC6A4, YWHAE                                                          |
| Parkinson Disease         | 0.166085      | 0.365388       | GSK3B, BCL2L1, RNF19A, CSNK1A1, ROCK1, CSNK1D, RB1, MAPT, ATF4, NEDD9, SNGC, KLC1, HSPA1A, SLC6A4, S100A10, APEX1, KLC3, ERC2C, YWHAE |
| Depression                | 0.239557      | 0.470752       | PRKCA, SLC6A4                                                                 |
| Attention Deficit Disorder with Hyperactivity | 0.946547 | 0.999994 | KIF6, SLC6A4 |
| Mental Retardation, Xlinked | 0.91368       | 0.999994       | POBP1, STK26, HDAC2, MBD1, RPS6KIA2, UPF3B |

Onset Alzheimer’s Disease, Early Intermediate Alzheimer’s Disease, Late Intellectual Disability Parkinsonian Disorders Schizophrenia, Paranoid Depression Attention Deficit Disorder with Hyperactivity Mental Retardation, Xlinked

Varidaki et al. Repositioning Microtubule Drugs for Brain

Repositioning Microtubule Drugs for Brain

Frontiers in Cellular Neuroscience | www.frontiersin.org 3 August 2018 | Volume 12 | Article 226
1960 to 1980. Taxol was shown to have cytotoxic activity in 1964 and its structure was resolved in 1971 (Wani et al., 1971). Extensive cancer cell anti-mitotic properties were characterized before taxol entered the clinics, 30 years after its discovery (Kingston, 1991). Nowadays, it is a first-line chemotherapy anti-cancer agent for treatment of breast and ovarian cancers (Wani et al., 1971). It exerts a broad-spectrum anti-tumor activity that is effective in both solid and dissociated tumors. Paclitaxel promotes microtubule assembly in vitro (Schiff and Horwitz, 1980) and reduces microtubule dynamics. To do this, it binds a single site on the β-tubulin subunit, on the inner surface near to the lateral protofilament interaction sites (Nogales et al., 1995, 1998). Taxol binding prevents compaction at the tubulin dimer interface and results in more stable lateral interactions. This reduces stochastic switching of microtubules between growth and shrinkage, a classical behavior known as “dynamic instability,” which is essential for normal functioning of the microtubule cytoskeleton (Alushin et al., 2014).

**BLOOD BRAIN BARRIER PENETRANCE**

One major drawback for the potential use of paclitaxel in the treatment of neurological and neuropsychiatric diseases is the limited bioavailability of this compound in brain. Taxol does not cross the blood brain barrier. Moreover, taxane family compounds are good substrates for P-glycoprotein transporters or multidrug resistance proteins, which are highly expressed in capillary endothelial cells that form the blood brain barrier (Schinkel et al., 1994; Fellner et al., 2002). P-glycoprotein transporters rapidly export taxanes out from cells into the bloodstream, reducing brain bioavailability and contributing to drug resistance. Smart delivery of paclitaxel in the brain has been investigated. For example, taxol conjugation to the brain delivery peptide Angiopep-2 was tested in efforts to improve its blood brain barrier permeability (Régina et al., 2008; Kurzrock et al., 2012). Angiopep-2 is a 19-mer peptide that binds to the lipoprotein related protein-1 receptor and triggers transcytosis. This approach can facilitate targeting of non-blood brain barrier penetrant drugs to the brain, as it provides a mechanism for the conjugated drug to cross the capillary epithelial cell layer. It may also assist selective targeting of cancer cells that exhibit high expression levels of the lipoprotein-related protein-1 receptor (US patent: WO2004060403 A2). ANG1005 (also known as GRN1005; US patent: US7557182 B2), is a conjugate of Angiopep-2 with paclitaxel. It underwent phase II clinical trials to determine its efficacy against breast cancer and non-small cell lung cancer primary tumors, and in patients suffering...
### TABLE 2 | Clinical trials describing brain penetrance and nervous system side effects for microtubule stabilizing agents.

| Name(s) | Cytoskeletal target | Diseases | Clinicaltrials.gov identifier (Status-study completion date) | BBB penetrance/side effects |
|---------|---------------------|----------|-------------------------------------------------------------|-----------------------------|
| Epothilone D (KOS-862, NSC-703147, desoxyepothilone B BMS-241027) | Tubulin | Alzheimer's Disease | NCT01492374 (C) (October 2013) | Brain penetrant/Neurotoxicity severe diarrhea |
| BMS-247550 (ixabepilone) | Tubulin | Lung cancer | NCT00080509 (T) (November 2004) NCT00081107(C) (December 2004) | Brain penetrant/CIN, neutropenia, nausea, fatigue, arthralgia, alopecia |
| BMS-247550 (ixabepilone) | Tubulin | Colorectal cancer | NCT00077259 (O) (September 2004) | Non-brain penetrant/Neutropenia |
| BMS-247550 (ixabepilone) | Tubulin | Breast cancer | NCT00337649 (O) (April 2008) | Non-brain penetrant/Neutropenia |
| BMS-247550 (ixabepilone) | Tubulin | Prostate cancer | NCT00104130 (T) (February 2005) | Non-brain penetrant/Neutropenia |
| BMS-310705 | Tubulin | Brain penetrant/neurotoxicity, severe diarrhea | | |
| NAP (AL-108, AL-208, davanetide NAPVSIPQ) | EB1/EB3 | Schizophrenia | NCT00505765 (O) (April 2009) | Brain penetrant/One patient reported palpitations |
| TPI 287 (ARC-100) | Unknown | Alzheimer's Disease | NCT01986666 (A) (Est. completion: March 2019) | Brain penetrant/ Seizures, Grade III CIN |
| Paclitaxel | Taxol-binding domain | Approved for ovarian, breast and non-small cell lung carcinomas, AIDS-related Kaposi’s Sarcoma | Numerous clinical trials | Non-brain penetrant/CIN, neutropenia |
| ANG1005 (GRN1005) | Taxol-binding domain | Brain metastasis | NCT01497665 (T) (February 2013) NCT02048059 (O) (September 2017) NCT01967810 (C) (September 2017) NCT01498989 (O) (October 2017) | Brain penetrant/neutropenia |
| Sagopilone (ZK-EPO, ZK 219477) | Tubulin | Brain metastasis | NCT00496379 (T) (January 2012) | Brain penetrant/fatigue, CIN, nausea,diarrhea, leucopenia hepatobiliary disorder |
| Triazolopyrimidines, Cevipabulin | Vinca site | Advanced malignant solid tumors | NCT00195247 (T) (Not mentioned) NCT00195325 (T) (Not mentioned) | Non brain penetrant/Not reported |
| IDN-5109 (BAY 59-8862, Ortaxaxel) | Tubulin | Recurrent glioblastoma | NCT01989884 (S) (December 2016) | Brain penetrant/Not reported |
| Cabazitaxel (Jevtana, XRP-6258) | Tubulin | Taxane-refractory NSCLC | NCT00054314 (O)(April 2003) NCT00044538 (O) (June 2004) | Brain penetrant/ hypotension, bronchospasm, generalized rash/erythema, severe diarrhea, neutropenia, neurotoxicity fatigue, alopecia, Grade 1 neurotoxicity |
| | | Metastatic breast cancer | NCT00044525 (O) (February 2004) | |
| | | Refractory Non-Hodgkin's Lymphoma | NCT00044551 (O) (July 2003) | |
| | | Renal cell carcinoma | NCT00044564 (O) (January 2003) | |
| | | Prostate cancer | NCT00417079 (O) (September 2009) | |

(Continued)
TABLE 2 | Continued

| Name(s)                  | Cytoskeletal target | Diseases                          | Clinicaltrials.gov identifier (Status-Study Completion Date) | BBB penetrant/side effects |
|--------------------------|---------------------|-----------------------------------|-------------------------------------------------------------|---------------------------|
| Head and neck cancer     |                     |                                   | NCT01620242 (C) (April 2015)                                  |                           |
| Breast cancer            |                     |                                   | NCT01934894 (T) (April 2017)                                  |                           |
| NSCLC                    |                     |                                   | NCT030498942 (A) (Est. completion: August 2022)               |                           |
| Refractory Glioblastoma  |                     |                                   | NCT014383027 (C) (September 2015)                             |                           |
| Multiforme               |                     |                                   | NCT01852578 (C) (August 2013)                                 |                           |
|                          |                     |                                   | NCT01866449 (C) (August 2017)                                 |                           |

from high-grade gliomas (NCT 01497665, NCT 02048059, NCT 01967810, and NCT 01480583). In patients with non-small lung cancer with brain metastasis, the prevailing side effect of this drug was peripheral neuropathy, observed in 37.50% of patients, and neutropenia, which affected 18.75% of patients (Table 2).

Another experimental delivery approach is paclitaxel-loaded nanoparticles conjugated to the Pep-1 peptide (Pep-NP-PTX). This delivery system introduced taxol to the brain via endocytosis of the interleukin-13 receptor subunit alpha-2 (IL-13RA2), which showed elevated expression in gliomas (Patent application: CN103655517 A). In mice, Pep-NP-PTX showed increased uptake to brain and increased cytostatic effect in glioma cells with no overt toxicity, suggesting that it could represent a viable delivery option (Wang et al., 2015). Yet as discussed below, peripheral neuropathy remains an expected side effect with paclitaxel.

CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common adverse side effects of paclitaxel treatment. 30–80% of patients will most likely develop CIPN, depending on the dose and duration of the treatment. Most often, these patients will continue to have CIPN symptoms even after discontinuing the treatment (Cavaletti and Marmiroli, 2010). Paclitaxel can induce acute signs of CIPN as early as 24 h after a single high dose treatment. In order to eliminate this side effect, researchers have studied the benefit of using albumin-coated paclitaxel (ABI-007-Abraxane, also known as nab-paclitaxel), a Food and Drug Administration (FDA)-approved medicine for breast, lung and pancreatic cancer (Ibrahim et al., 2005; Nyman et al., 2005). Albumin-bound paclitaxel produced fewer >grade-3 neuropathies, neutropenia and myalgia in non-small cell lung carcinoma patients than did soluble paclitaxel in a phase III trial (Socinski et al., 2012). However meta-analysis of Abraxane use for treatment of breast cancer (including 2357 patients) concluded that the complete response rate was increased but CIPN side effects were aggravated compared to classical taxanes (Zong et al., 2017). Also, in a phase III study of metastatic breast cancer (NCT 00046527), grade-3 sensory neuropathy was increased in patients receiving Abraxane compared to paclitaxel, although this could be attributed to the higher dose of Abraxane used (Gradishar et al., 2005).

Understanding the mechanism whereby paclitaxel induces CIPN may be beneficial in developing strategies to avoid or ameliorate symptoms of neuropathic pain in patients treated with microtubule stabilizing agents. To this end, it was recently shown that microtubule stabilization by paclitaxel decreases axonal transport and downregulates translation of bclw mRNA in axons. This in turn leads to activation of a degenerative cascade triggered by mitochondrial dysfunction and activation of the proteolytic enzyme calpain and subsequent axonal degradation (Pease–Raissi et al., 2017). Cognitive deficit is a more recently recognized side effect of chemotherapy, especially in elderly patients (Mandilaras et al., 2013). It will be interesting to see whether drugs with reduced CIPN will also show less cognitive side effects.

CABAZITAXEL

Cabazitaxel (Jevtana, XRP-6258) is a second-generation microtubule-binding drug from the taxane family. It received approval by the FDA in 2010 for the treatment of refractory metastatic prostate cancer (Abidi, 2013). A phase III study (NCT 00417079) of patients with metastatic prostate cancer showed that Cabazitaxel prolonged the survival rate of the patients, with only 1% of patients suffering from grade-3 peripheral neuropathy (de Bono et al., 2010). Cabazitaxel is an attractive anticancer compound compared to paclitaxel as it displays poor affinity for the P-glycoprotein receptor multi-drug resistance pump and as a consequence is blood-brain penetrant (Cisternino et al., 2003). As such, phase II trial (NCT 01886449) used it for treatment of refractory glioblastoma multiforme. Cabazitaxel underwent evaluation for its efficacy in ameliorating pediatric brain tumors such as atypical teratoid rhabdoid tumors, medulloblastomas, and central nervous system primitive neuroectodermal tumors (Girard et al., 2015). Like classical taxanes, cabazitaxel exerts anti-proliferative and pro-apoptotic effects in glioma while disrupting cell cycle by its effects on the microtubule cytoskeleton. Remarkably, it does this at a dose that is non-toxic to surrounding primary neurons and astrocytes (Ghoochani et al., 2016), suggesting that low levels could be viable for treatment of microtubule disorders in brain, in addition to tumors.
DISCODERMOLIDE AND ITS ANALOG DICTYOSTATIN

Discodermolide is a polyhydroxylated lactone that was isolated from the marine sponge Discodermia dissolue (Gunasekera et al., 1990). This compound stabilizes microtubules more potently than paclitaxel and retains anti-tumor activity in cell lines that express high levels of P-glycoprotein and are normally resistant to taxanes (Kowalski et al., 1997). Discodermolide binds with higher affinity to tubulin dimers compared to paclitaxel. X-ray crystallography has shown that discodermolide binds the tubulin pocket of β-tubulin, but it does this differently to paclitaxel (Sáez-Calvo et al., 2017). More specifically, while paclitaxel binds to the M-loop of tubulin, discodermolide binds preferentially to the N-terminal H1S2 loop, helping to promote a synergistic effect of these two drugs (Martello et al., 2000; Khrapunovich-Baine et al., 2009). Discodermolide has been in phase I clinical trials for treatment of advanced solid malignancies, where patients did not display any severe neuropathy or neutropenia but did show signs of pulmonary toxicity (Mita et al., 2004). The discodermolide analog dictyostatin has comparable properties to discodermolide in terms of tubulin binding and polymerization (Madiraju et al., 2005). However, dictyostatin shows improved brain bioavailability, 55-times higher than that of discodermolide. Dictyostatin increases levels of acetylated tubulin in brains of mice, indicating that it increases microtubule stability in vivo, as expected. Indeed, dictyostatin is a more potent microtubule-stabilizing agent when compared to discodermolide (Brunden et al., 2013). This together with its improved pharmacodynamic properties suggest that dictyostatin could be suitable for treating central nervous system disorders.

EPOTHILOINES

The Epothilones are pharmacological agents comprising 16-membered macrocyclic lactones isolated from the soil dwelling bacteria Sorangium cellulosum (Hoele et al., 1993) (Patent number: DE4138042 A1). Like taxol, they bind and stabilize microtubule polymers, promoting stabilization at sub-micromolar concentrations and inducing cytotoxicity through cell cycle arrest (Bollag et al., 1995; Giannakakou et al., 2000; Nettles et al., 2004). Epothilones have additional advantages that confer increased potency compared to other anti-neoplastic agents. They are water-soluble and amenable to large-scale production through bacterial fermentation. Most importantly however, epothilones are also poor substrates for the P-glycoprotein transport pump, thereby increasing brain bioavailability (Bollag et al., 1995; Aller et al., 2009).

EPOTHILOCNE ANALOGS AND CLINICAL TRIALS

Since its first identification, several epothilone analogs underwent synthesis resulting in higher anti-tumor efficacy compared to paclitaxel (EPO906) and the original natural compound epothilones A and B (Hoele et al., 1993). Among these, epothilone B shows the highest potency. Analogs of epothilone B, such as epothilone D (BMS-241027) display a maximum tolerated dose of 25 mg/kg compared to 0.3 mg/kg for epothilone B (Chou et al., 1998). Moreover, the activity of BMS-247550 (also known as ixabepilone), a lactam analog of epothilone B, is twice as high as paclitaxel (Lee et al., 2001). Another epothilone B analog, BMS-310705, was developed to improve compound solubility, however clinical development was discontinued due to associated severe toxic side-effects and because ixabepilone received FDA approval for treatment of breast cancer (Overmoyer et al., 2005; Sessa et al., 2007; Brogdon et al., 2014).

Additionally, sagopilone (ZK-EPO, ZK-Epithilone, ZK 219477) was developed as the first synthetic epothilone designed for cancer treatment (Klar et al., 2006). It shows good brain bioavailability (Hoffmann et al., 2009), and entered phase II trial for breast cancer metastasis (NCT 00496379). However, the trial terminated; side effects of this compound included fatigue, nausea, diarrhea, leucopenia, CIPN and hepatobiliary disorders (Freedman et al., 2011).

EPOTHILOINES IN ANIMAL MODELS OF NEURODEGENERATION AND SPINAL CORD INJURY

In experimental studies, epothilones underwent testing against several brain diseases, including tauopathies and Parkinson’s disease (Brunden et al., 2011; Ruschel et al., 2015). More specifically systemic injection of a low dose (0.75 mg/mg body weight) of epothilone B to rats following spinal cord injury promoted axonal recovery (Ruschel et al., 2015). Interestingly, in the same experiments, epothilene B also reduced fibrotic scar formation. The microtubule-stabilizing drug at once reduced microtubule polarization in fibroblasts, while promoting microtubule polarization in neurons. By this means, it facilitated axon regrowth into the injured area. This groundbreaking study suggested that epotheline B could be useful for clinical treatment of CNS injury. A later study addressed the effect of epothilene B on physiological pruning of axonal branches and synapses. Studying the neuromuscular junction, the authors identified that disassembly of synapses was elicited locally by microtubule disassembly and that a single injection with epothilone B slowed this synapse elimination (Brill et al., 2016). The effect attributed to stabilization of microtubules because EB3 comet density reduced and tubulin content increased. Together these studies provided impetus to harness microtubule-stabilizing drugs such as epothilone B for therapy. More recently, epothilone D was shown to facilitate recovery of hind limb function after spinal cord injury in rats (Sandner et al., 2018), yet in the SOD1G93A mouse model of ALS, epothilone D accelerated disease progression (Clark et al., 2018), indicating that more work is needed in a variety of models.
POTENTIAL BENEFITS OF EPOTHILONES FOR TAUOPATHIES

Study of paclitaxel binding to microtubules revealed that it displaced Tau from microtubules, suggesting that paclitaxel and tau share a common binding site and microtubule stabilization mechanism (Kar et al., 2003). Tauopathies represent a class of neurodegenerative diseases where there is pathological aggregation of Tau. Hyper-phosphorylated Tau, a pathological hallmark of tauopathies, binds more poorly to microtubules and forms filamentous or amorphous aggregates (Iqbal et al., 2010). Epothilones provide a potential means to recover microtubule stability in the absence of this endogenous stabilizer.

Epothilone D has proven beneficial for amelioration of Tau-related pathologies in experimental animal models, where Tau mis-folding leads to impaired microtubule stability. The widely utilized MAPT (Tau)-PS19 transgenic mice are one such example. These mice harbor the disease-associated P301S mutation that gives rise to “4T” Tau, which harbors four microtubule-binding domains. The expression of Tau in PS19 mice is five-fold higher than endogenous levels, and they develop hallmarks of Alzheimer's disease including neuronal loss in the hippocampus, spreading the neocortex and entorhinal cortex. They also develop neurofibrillary-like inclusions accompanied by micro-gliosis, astrocytosis, although notably they do not develop amyloid plaques (Yoshiyama et al., 2007). Low doses of epothilone D (lower than those used in phase II clinical trials), increased microtubule density in MAPT(Tau)-PS19 mice. The drug also reduced axonal dystrophy and enhanced cognitive performance (Brunden et al., 2010). Furthermore, in neuronal cultures from amyloid precursor protein-mice, epothilone D treatment increased dendritic spine density (Penazzi et al., 2016). Because of such findings, epothilone D underwent clinical trial investigation in patients with mild Alzheimer’s disease. In these studies, Tau provided a biomarker readout from cerebrospinal fluid; while cognitive performance and functional magnetic resonance imaging were additional outcome measures (NT0 1492374). This trial ended and further investigation of epothilone D discontinued. No results are posted so far (Tables 1, 2; Figure 1).

In the rTg4510 Alzheimer’s mouse model, where P301L is conditionally expressed, stochastic microtubule dynamics decrease. Injection with epothilone D recovered baseline dynamics and improved cognitive function in these mice (Barten et al., 2012). A follow up study showed that epothilone D treatment reversed several other features such as microtubule density, axonal dystrophy, and insoluble Tau. Thus, pathological Tau-related hallmarks reduced without any notable side effects in Tau transgenic mice (Zhang et al., 2012). An important finding from these experiments was that epothilone D, by stabilizing microtubule polymers, restored microtubule dynamics. Counter intuitively perhaps, drug-induced stabilization of microtubules did not immobilize them in a way that perturbed normal physiological regulation. This finding increased expectation that this molecule, or its analogs, could provide a beneficial treatment for Alzheimer’s disease. However, following a phase I trial that used epothilone D for Alzheimer’s disease discontinued, a new trial commenced and results are awaited (NCT 01966666).

POTENTIAL BENEFIT OF EPOTHILONES FOR PARKINSON’S DISEASE

Epothilone D treatment ameliorates hallmarks of Parkinson’s disease in animal models. Degeneration of nigrostriatal dopaminergic neurons in the substantia nigra pars compacta is the disease-defining hallmark of Parkinson’s disease in patients. In recent years, there is emerging evidence that microtubule instability may contribute to the disease etiology. For example MAPT(Tau)-containing neurofibrillary tangles are observed in both Parkinson’s and Alzheimer’s patients (Bancher et al., 1987; Joachim et al., 1987). Moreover, MAPT(Tau) variants confer genetic risk for Parkinson’s disease (Simón–Sánchez et al., 2009). Furthermore, the environmental toxin rotenone, exposure to which is associated with increased risk to develop Parkinson’s disease, destabilizes microtubules leading to cell-specific toxicity of midbrain dopaminergic neurons. Microtubule stabilizing drugs such as taxol rescued viability in these neurons (Ren et al., 2005). Similarly, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson’s disease, epothilone D treatment prevented the loss of dopaminergic neurons in the substantia nigra pars compacta. These effects were attributed to the rescue of microtubule instability induced by MPTP (Cartelli et al., 2013; Killinger and Moszczynska, 2016).

POTENTIAL BENEFIT OF EPOTHILONES FOR PSYCHIATRIC DISORDERS

The effect of epothilone D was tested in mice lacking the gene for microtubule-associated protein-6 (MAP6)/stable tubule only polypeptide (STOP). These mice are used as a model for psychiatric disorders because they exhibit anatomical and behavioral hallmarks associated with schizophrenia that are reversible by treatment with anti-psychotic drugs. For example they display depressed and anxious behavior, altered serotoninergic tone and impaired cognitive function (Fournet et al., 2012; Marchisella et al., 2016), while diffusion tensor imaging of MAP6 knockout mice revealed several neuronal tract deficits (Gimenez et al., 2017). In addition, they show impaired sensorimotor gating in the pre-pulse inhibition paradigm, and hyperactivity in a locomotor test, compared to their wild-type littermates (Volle et al., 2013). Promising results were obtained with epothilone D in these mice, where treatment induced an increase in synapse density and improved synaptic function measured by long-term potentiation (Andrieux et al., 2006). While preliminary, the association of anomalies in genes encoding microtubule-stabilizing proteins with psychiatric disorders (Marchisella et al., 2016), suggests that more widespread testing of epothilone and other microtubule stabilizing drugs in similar models is warranted.
TPI-287—ANTI-TUMOR AGENT IN CLINICAL TRIALS FOR TREATMENT OF NEURODEGENERATIVE DISEASES

TPI-287 is a third generation taxane (US patents: US7879904 and US7745650). It is a semisynthetic derivative of abeo-taxane and is widely used in cancer therapy. Like other taxanes, TPI-287 binds to tubulin and promotes microtubule stabilization and as a small molecule, it has the ability to cross the blood brain barrier. Experimentally it was investigated as a drug to treat breast cancer that had metastasised to brain. It effectively reduced tumor size after intravenous administration, however unpublished data indicated that there was loss of body weight as a side effect of treatment (Fitzgerald et al., 2012). TPI-287 is in Phase I clinical trial for treatment of mild to moderate symptoms of Alzheimer’s disease (NCT 01966666). In this trial, three arms of patients receive different doses of TPI-287, following which patients are monitored for improvement in cognitive function. In addition, Aβ and Tau biomarker expression is measured from cerebrospinal fluid biopsies. The primary goal is to determine the maximum tolerated dose. TPI-287 is also in phase I (NCT 02133846) for treatment of primary 4-repeat tauopathies (4RT), corticobasal syndrome (CBS; or corticobasal degeneration) and progressive supranuclear palsy. Even though both clinical trials are active, and no side effects were reported so far. A completed phase I trial for treatment of neuroblastoma used higher TPI-287 doses (NCT 00867568 and NCT 01483820). These reported that 16.67% of patients showed serious side effects, such as seizures. Also, phase I clinical trial for metastatic melanoma (NCT 01067066) showed that 24% of the patients exhibited grade-3 peripheral neuropathy (McQuade et al., 2016).

IDN-5109

IDN-5109 (BAY 59-8862, Ortaxalax) also belongs to the third generation of taxanes. It is possible to administer orally and it is more active than paclitaxel, displaying also greater solubility (Polizzi et al., 1999; Nicoletti et al., 2006; Jordan et al., 2002). It is a blood-brain barrier penetrant taxane analog, exhibiting a 15-fold higher brain to plasma ratio (Laccabue et al., 2001). Currently, IDN-5109 is in phase II for recurrent glioblastoma (NCT 01989884), taxane-refractory non-small-lung cell carcinoma (NCT 00054314 and NCT 00044538) and metastatic breast cancer (NCT 00044525), refractory NonHodgkin’s lymphoma (NCT 00044551) and renal cell carcinoma (NCT 00044564). Clearly, it will be of interest to establish whether neuropathy side effects diminish with this compound. Testing in models of brain disorders is still awaiting.

NON-TAXANE GROUP MICROTUBULE STABILIZERS: NAP AND D-SAL

NAP, also known as davunetide, is an intranasal neuropeptide (NAPVSIPOQ) derived from the activity-dependent neuroprotective protein (ADNP). The minimal 8 amino acid peptide NAP is neuroprotective (Gozes et al., 2005). ADNP mRNA levels have been shown to be dysregulated in Alzheimer’s disease and in schizophrenia (Matsuoka et al., 2008; Dresner et al., 2011; Merenlender–Wagner et al., 2015; Ivashko–Pachima et al., 2017; Sragovich et al., 2017), and mutations in the ADNP gene have been found in patients with autism spectrum disorder (Helsmoortel et al., 2014). Clinical symptoms in patients carrying the ADNP mutation, so called Helsmoortel-Van der Aa syndrome or ADNP syndrome, have been well characterized (Van Dijck et al., 2018). The mechanism of action of NAP is believed to involve microtubules. NAP decorates microtubules in cultured cells, although in a purified system, increasing concentrations of NAP failed to induce tubulin polymerization (YenJerla et al., 2010). More recently however, NAP was shown to interact with microtubule end-binding proteins EB1 and EB3, leading to increased dendritic spine density (Oz et al., 2014). Furthermore, NAP increases Tau binding to EB1/EB3 as part of its cyto-protective mechanism (Gozes et al., 2017, 2018; Ivashko–Pachima et al., 2017). ADNP also participates in the mammalian SWI/SNF complex, which is a multiprotein chromatin-remodeling complex (Mandel and Gozes, 2007).

Potentially Beneficial of NAP for Treatment of Psychiatric and Neurodegenerative Disorders

Interestingly, NAP is brain penetrant when administered either by intranasal delivery (AL-108) (Gozes et al., 2000), intravenously (AL-208) (Leker et al., 2002) or intraperitoneally (Spong et al., 2001). NAP can exert its neuroprotective effects at very low concentrations, improving short-term memory in Apo-E mice, a mouse model for Alzheimer’s disease (Bassan et al., 1999). Like the L-isomer, the D-amino acid analog of NAP (D-NAP) is also neuroprotective and D-NAP also improves cognitive deficits in Apo-E mice (Brenneman et al., 2004). In the Thy-α-Syn mouse model of Parkinson’s disease, where human α-synuclein expression is under the control of the Thy-1 promoter, NAP treatment reduces both phosphorylated tau and α-synuclein aggregates in the substantia nigra (Fleming et al., 2011; Magen et al., 2014). This decrease in hyper-phosphorylated Tau is also evident in a mouse model of Alzheimer’s disease, where NAP enhances axonal transport and improves cognitive performance in the Morris water maze (Matsuoka et al., 2008; Jouroukhin et al., 2013). Additionally, NAP promotes microtubule invasion into neuronal growth cones (Oz et al., 2012). Thus, NAP appears to promote microtubule stability by increasing the affinity of microtubules for Tau binding. Notably, NAP blocks phosphorylation of Tau on Ser-262 (Magen et al., 2014), a residue required for EB1/EB3 interaction (Ramirez–Rios et al., 2016). It is therefore likely that reduction of hyper-phosphorylated Tau by NAP is central for its mechanism (Quraisha et al., 2013; Ivashko–Pachima et al., 2017). Moreover, ADNP itself shows potential as a blood biomarker for Alzheimer’s disease (Malishkevich et al., 2016).

Significantly, in the context of psychiatric disorders, NAP reverses the hyperactivity of MAP6/STOP null mice, a mouse model for schizophrenia (Merenlender–Wagner et al., 2010).
Moreover, NAP treatment prevents neuronal death often seen with clozapine, a commonly used anti-psychotic drug for treatment of schizophrenia (Merenlender–Wagner et al., 2014). Moreover, NAP reduces depressive-like behavior in mice following social isolation, exemplified by reduced immobility in the forced swim test and reduced anhedonic phenotype (Liu et al., 2017). NAP administration in DISC1 knockout mice, a model for schizophrenia, reduces anxiety levels in the elevated plus maze. On the other hand, combined treatment with the antipsychotic drug risperidone, failed to induce the same anxiolytic response. The authors attributed this to occlusion of the NAP binding site on microtubules by risperidone (Vaisburd et al., 2015). This indicates once more that the mode of action of NAP involves microtubules.

NAP is currently in phase II trial (NCT 00505765) for treatment of schizophrenia where the effect of intranasal NAP (AL-108) administration at two different doses is assessed. This derives from positive results in an earlier study using the UCSD performance based skills assessment (UPSA). While there was no significant improvement in cognitive scoring, the UPSA score showed significant improvement in functional capacity among patients (Javitt et al., 2012). A follow-up, double-blind study demonstrated no effect of a high dose of NAP (davunetide) in elevating N-acetylaspartate (Jarskog et al., 2013), a metabolite that is proposed to be slightly reduced in schizophrenia patients, although this is controversial (Steen et al., 2005). Moreover, NAP is in phase II trial (NCT 01056965) to assess its effects on mild cognitive impairment in Alzheimer’s disease. Earlier analysis showed that NAP was well tolerated by Alzheimer’s patients with no obvious side effects, and there was some improvement in individual memory tasks but not for composite memory score (Gozes et al., 2009; Morimoto et al., 2013). As an extension of the NAP studies, a shorter 4-amino acid peptide termed “SKIP” which is binds the EB binding site of ADNP is being studied in animal models for potential applications in psychiatric disorders (Amram et al., 2016).

TRIAZOLOPYRIMIDINES

Triazolopyrimidines are non-naturally occurring microtubule stabilizing compounds. Rather than acting like other microtubule stabilizing drugs, to stabilize the lateral edges, they bind in the vinca-site, normally targeted by agents such as vinblastine, acting to stabilize the longitudinal contacts between tubulin subunits (Sáez-Calvo et al., 2017). Triazolopyrimidines display similar properties to other microtubule stabilizing agents in promoting microtubule polymerization. Some of these compounds CNDR-51549 and CNDR51555 (US patent: US20170173016 A1) are capable of crossing the blood-brain barrier and increase the acetylated form of tubulin which reflects the stable pool (Lou et al., 2014; Cornc et al., 2015). Moreover, CNDR-51657 is capable of reducing hyperphosphorylated Tau induced by okadaic acid treatment (Kovalevich et al., 2016). Cevipabulin (TTI-237) (Beyer et al., 2008), another compound from this family which is not brain penetrant, has undergone phase I clinical trials for treatment of advanced malignant solid tumors (NCT 00195247 and NCT 00195325).

CONCLUSIONS

Finding new treatments for neurological disorders has proven to be an extremely challenging task. The realization that microtubule disruption plays a central role in brain disease opens up the possibility to benefit from knowledge gained from existing cancer therapeutics. Starting with the discovery of taxol in a National Cancer Institute-funded screening program in 1962, an array of brain penetrant microtubule stabilizers were developed with the goal of treating gliomas. Now, microtubule-stabilizing agents are under investigation for treatment of a variety of brain disorders. While this endeavor has not been without hurdles, we can expect that the high demand for therapeutic breakthroughs in this area will drive progress toward successful clinical outcome. In a field where receptor drugs dominate, this represents a completely new departure that looks promising.

AUTHOR CONTRIBUTIONS

AV, YH, and EC contributed to the conception and writing of the manuscript.

FUNDING

This work was funded by Åbo Akademi University, the Academy of Finland, MATTI, and Mol Bio Doctoral Programmes, Marie Curie r’BIRTH ITN.

ACKNOWLEDGMENTS

We are grateful to Peter James, Lund University for assistance with MetaCore TR.

REFERENCES

Abidi, A. (2013). Cabazitaxel—a novel taxane for metastatic castration-resistant prostate cancer—current implications and future prospects. J. Pharmacol. Pharmacother., 4, 230–237. doi: 10.4103/0976–500X.119704

Ackerley, S. A. J., Grierson, B. S., Perkinton, M. S., Brownlees, J., Byers, H. L., Miller, C. C. et al. (2004). p38alpha stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 26, 354–364. doi: 10.1016/j.mcn.2004.02.009

Allet, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., et al. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718–1722. doi: 10.1126/science.1168750

Alushin, G. M., Lander, G. C., Kellogg, E. H., Zhang, R., Baker, D., and Nogales, E. (2014). High-resolution microtubule structures reveal the structural transitions in αβ–tubulin upon GTP hydrolysis. Cell 157, 1117–1129. doi: 10.1016/j.cell.2014.03.053

Amram, N., Hacohen–Kleiman, G., Srugovich, S., Malishkevich, A., Katz, J., Touloumi, O., et al. (2016). Sexual divergence in microtubule function, the
novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory. Mol. Psychiatry 21, 1467–1476. doi: 10.1038/mp.2015.208

Andrieux, A., Salin, P., Schweitzer, A., Begou, M., Pachoud, B., Brun, P., et al. (2006). Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Biol. Psychiatry 60, 1224–1230. doi: 10.1016/j.biopsych.2006.03.048

Bancher, C., Lassmann, H., Budka, H., Grundke–Iqbal, L, Iqbal, K., Wiche, G., et al. (1987). Neurofibrillary tangles in Alzheimer's disease and progressive supranuclear palsy, antigenic similarities and differences. Microtubule–associated protein tau antigenicity is prominent in all types of tangles. Acta Neuropathol. 74, 39–46. doi: 10.1007/BF00688336

Barten, D. M., Fanara, P., Andorfer, C., Hoque, N., Wong, P. Y., Husted, K. H., et al. (2014). Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule–stabilizing agent BMS—241027. J. Neurosci. 32, 7137–7145. doi: 10.1523/JNEUROSCI.0188–12.2012

Bassan, M., Zamostiano, R., Davidson, A., Pinhasov, A., Giladi, E., Perl, O., et al. (1999). Complete sequence of a novel protein containing a femtomolar–activity–dependent neuroprotective peptide. J. Neurochem. 72, 1283–1293. doi: 10.1046/j.1471–4159.1999.0721283.x

Beasley, C., Cotter, D., and Everall, I. (2002). An investigation of the Wnt–signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder. Schizophr. Res. 58, 63–67. doi: 10.1016/S0920–9964(01)00376–0

Bernard, R., Kerman, J. A., Thompson, R. C., Jones, E. G., Bunney, W. E., Barchas, J. D., et al. (2011). Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol. Psychiatry 16, 634–646. doi: 10.1038/mp.2010.44

Beyer, C. F., Zhang, N., Hernandez, R., Vitale, D., Lucas, J., Nguyen, T., et al. (2018). Epothilone D accelerates disease progression in the SOD1(G93A) Neuropathol. Appl. Neurobiol. doi: 10.1111/an.12473. [Epub ahead of print].

Beyer, C. F., Zhang, N., Hernandez, R., Vitale, D., Lucas, J., Nguyen, T., et al. (2018). Epothilone D accelerates disease progression in the SOD1(G93A) Neuropathol. Appl. Neurobiol. doi: 10.1111/an.12473. [Epub ahead of print].

Bueno, J. S., Oudard, S., Ozgurozlu, M., Hansen, S., Machiels, J. P., Kocak, I., et al. (2010). Predniso plus cabazitaxel or mitoxantrone for metastatic castration–resistant prostate cancer progressing after docetaxel treatment, a randomised open–label trial. Lancet 376, 1147–1154. doi: 10.1016/S0140–6736(10)61839–X

Cisternino, A. S., James, M. J., Kovalevich, J., Trojanowski, J. Q., Lee, V. M., Smith, A. B. III, et al. (2015). Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)–stabilizing triazolopyrimidine. Bioorg. Med. Chem. Lett. 25, 4980–4982. doi: 10.1016/j.bmcl.2015.03.002

Cornec, A. S., James, M. I., Kovalievich, J., Trojanowski, J. Q., Lee, V. M., Smith, A. B. III, et al. (2015). Activity–dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2, deregulation in schizophrenia. Eur. Neuropsychopharmacol. 25, 351–365. doi: 10.1016/j.euroneuro.2010.06.004

Cleveland, D. W., Kirschner, M. W., and Cowan, N. J. (1978). Isolation of separate mRNAs for alpha– and beta–tubulin and characterization of the corresponding in vivo translation products. Cell 15, 1021–1031. doi: 10.1016/0092–6673(78)90289–6

Cote, J. M., and Scherrmann, J. M. (2003). Nonlinear accumulation in the brain of the taxoid TDX258 following saturation of P–glycoprotein at the blood–brain barrier in mice and rats. Br. J. Pharmacol. 138, 1367–1375. doi: 10.1038/sj.bjp.0705150

Craige, T. A., Blizzard, C. A., Breslin, M. C., Yeaman, E. J., Lee, K. M., Chuckowree, J., et al. (2018). Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. J. Neurochem. 68, 2292–2300. doi: 10.1158/0008–5472.CAN–07–1420

Da Costa, T. M., et al. (2011). Decreased protein levels of stathmin in adult brains with Alzheimer’s disease. Acta Neuropathol. 121, 281–288. doi: 10.1007/s00401–010–1025–0

Daniel, B., Bloch, J. A., and Corcione, A. R., et al. (2005). Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 102, 8627–8632. doi: 10.1073/pnas.050515102

Daniel, B., Bloch, J. A., and Corcione, A. R., et al. (2005). Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 102, 8627–8632. doi: 10.1073/pnas.050515102

De Conte, S., Cornec, A. S., James, M. J., Kovalevich, J., Trojanowski, J. Q., Lee, V. M., Smith, A. B. III, et al. (2015). Activity–dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2, deregulation in schizophrenia. Eur. Neuropsychopharmacol. 25, 351–365. doi: 10.1016/j.euroneuro.2010.06.004

Dresner, E., Agam, G., and Gozes, I. (2011). Activity–dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2, deregulation in schizophrenia. Eur. Neuropsychopharmacol. 25, 351–365. doi: 10.1016/j.euroneuro.2010.06.004

Engidawork, E., Guleserian, T., Yoo, B. C., Cairns, N., and Lubec, G. (2001). Alteration of caspases and apoptosis–related proteins in brains of patients with Alzheimer’s disease. Biochem. Biophys. Res. Commun. 281, 84–93. doi: 10.1016/j.bbrc.2001.04.036

Engmann, O., Hortobagyi, T., Thompson, A. J., Guadagno, J., Troakes, C., Soriano, E., et al. (2011). Cyclin–dependent kinase 5 activator p25 is generated during memory storage and is reduced at an early stage in Alzheimer’s disease. Biol. Psychiatry 70, 159–168. doi: 10.1016/j.biopsych.2011.04.011

Evans, T. A., Raina, A. K., Delacourte, A., Aprilekova, O., Lee, H. G., Zhu, X., et al. (2007). BCCA1 may modulate neuronal cell cycle re–entry in Alzheimer disease. Int. J. Med. Sci. 4, 140–145. doi: 10.7150/ijms.4.140

Fellner, S., Bauer, B., Miller, D. S., Schaffrik, M., Fankhanel, M., Spruss, T., et al. (2002). Transport of paclitaxel (Taxol) across the blood–brain barrier in vitro. J. Clin. Invest. 110, 1309–1318. doi: 10.1172/JCI215451

Figueira, D. J., Morris, J. A., Ma, L., Kandpal, G., Chen, E., Li, Y. M., et al. (2002). P.prefixin–dependent gamma–secretase activity modulates neurite outgrowth. Neurobiol. Dis. 9, 49–60. doi: 10.1016/s0929–4933(01)00147–2

Fleming, S. M., Mulligan, C. K., Richter, F., Mortazavi, A., Lemesre, V., Frias, C., et al. (2011). A pilot trial of the microtubule–interacting peptide (NAP) in mice overexpressing alpha–synuclein shows improvement in motor function and reduction of alpha–synuclein inclusions. Mol. Cell Neurosci. 46, 597–606. doi: 10.1016/j.mcn.2010.12.011
molecules with differential microtubule-stabilizing activities developed as potential therapeutic agents for Alzheimer’s disease and related tauopathies. J. Pharmacol. Exp. Ther. 357, 432–450. doi: 10.1124/jpet.115.231175
Kowalski, R. J., Giannakakou, P., Gunasekera, S. P., Longley, R. E., Day, B. W., and Hamel, E. (1997). The microtubule–stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel–resistant cells. Mol. Pharmacol. 52, 613–622. doi:10.1124/mol.52.4.611
Krüger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., et al. (1998). Ala30Pro mutation in the gene encoding alpha–synuclein in Parkinson’s disease. Nat. Genet. 18, 106–108. doi: 10.1038/ng0928-106
Kurzrock, R., Gabrail, N., Chandhassin, C., Moulder, S., Smith, C., Brenner, A., et al. (2012). Safety, pharmacokinetics, and activity of GN10105, a novel conjugate of angiopoietin–2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol. Cancer Ther. 11, 308–316. doi:10.1158/1535-7155.MCT-11-0566
Kwok, J. B., Hallupp, M., Loy, C. T., Chan, D. K., Woo, J., Mellick, G. D., et al. (2005). GSK3B polymorphisms alter transcription and splicing in Parkinson’s disease. Ann. Neurol. 58, 829–839. doi:10.1002/ana.20691
Laccabue, D., Tortoreto, M., Veneroni, S., Perego, P., Scanziani, E., Zucchetti, M., et al. (2001). A novel taxane active against an orthotopically growing human glioma xenograft. Cancer 92, 3085–3092. doi: 10.1002/1097–0142(20011125)92:12<3085::AID-CANC10150>3.0.CO;2-S
Lee, F. Y., Borzilleri, R., Fairchild, C. R., Kim, S. H., Long, B. H., Reventos–Suarez, M., Kurzrock, R., Gabrail, N., Chandhasin, C., Moulder, S., Smith, C., Brenner, A., et al. (2002). NAP, a femtomolar–acting peptide, protects the brain against ischemic injury by reducing apoptotic death. J. Clin. Neurosci 9, 1429–1437.
Leier, R. R., Teichner, A., Grigoriadis, N., Ovadia, H., Brenneman, D. E., Fridkin, M., et al. (2002). A novel taxane–interacting agent, NAPVI50Q, reduces tau phosphorylation in a transgenic caenorhabditis elegans model of Alzheimer’s disease. Mol. Neurobiol. 58, 829–839. doi:10.1002/ana.20691
Mandal, S., and Gozes, I. (2007). Activity–dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J. Biol. Chem. 282, 34448–34456. doi:10.1074/jbc.M704756200
Mandilaras, V., Van–Chow–Wah, D., Monette, J., Gaba, F., Monette, M., and Alfonso, L. (2013). The impact of cancer therapy on cognition in the elderly. Front. Pharmacol. 4:48. doi: 10.3389/fphar.2013.00048
Marchisella, F., Coffey, E. T., and Hollos, P. (2016). Microtubule and microtubule associated protein anomalies in psychiatric disease. Cytoskeleton (Hoboken) 73, 596–611. doi:10.1002/cm.21300
Martello, L. A., McDaid, H. M., Regl, D. L., Yang, C. P., Meng, D., Pettus, T. R., et al. (2000). Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin. Cancer Res. 6, 1978–1987.
Matamoros, A. J., and Baas, P. W. (2016). Microtubules in health and degenerative disease of the nervous system. Brain Res. Bull. 126, 217–225. doi:10.1016/j.brainresbull.2016.06.016
Matsuoka, Y., Jouroukhin, Y., Gray, A. J., Ma, L., Hirata–Fukae, C., Li, H. F., et al. (2008). A neuronal microtubule–interacting agent, NAPVISQP, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer’s disease. J. Pharmacol. Exp. Ther. 325, 146–153. doi:10.1124/jpet.107.130526
McQuade, J. L., Posada, I. P., Lecagooporn, C., Cain, S., Bassett Jr, R. L., Patel, S. P., et al. (2016). A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Res. 26, 604–608. doi:10.1097/CMR.0000000000000296
Merenlender–Wagner, A., Malishkevich, A., Shemer, Z., Udawela, M., Gibbons, A., Scarr, E., et al. (2015). Autophagy has a key role in the pathophysiology of schizophrenia. Mol. Psychiatry 20, 126–132. doi:10.1038/mp.2013.174
Merenlender–Wagner, A., Pikman, R., Giladi, E., Andrieux, A., and Gozes, I. (2010). NAP (davunetide) enhances cognitive behavior in the STOP heterogeneous mouse–a microtubule–deficient model of schizophrenia. Peptides 31, 1368–1373. doi:10.1016/j.peptides.2010.04.011
Merenlender–Wagner, A., Shemer, Z., Touloumi, O., Lagoudaki, R., Giladi, E., Andrieux, A., et al. (2014). New horizons in schizophrenia treatment, autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy 10, 2324–2332. doi:10.4161/15548627.2014.984274
Mita, A., Lockhart, A. C., Chen, T. L., Bochinski, K., Curtright, J., Cooper, W., et al. (2004). A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies. J. Clin. Oncol. 22, 2025–2025. doi:10.1200/jco.2004.22.14_suppl2025
Morrison, J. H., Schmeichel, D., Hirman, J., Blackwell, A., Keith, J., and Gold, M. (2013). A double–blind, placebo–controlled, ascending–dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL–108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 35, 325–336. doi:10.1159/000348347
Mullan, C., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., et al. (1992). A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N–terminus of beta–amyloid. Nat. Genet. 1, 345–347. doi: 10.1038/ng0892-345
Naj, A. C., Beecham, G. W., Martin, E. R., Gallins, P. J., Powell, E. H., Konidari, I., et al. (2010). Dementia revealed, novel chromosome 6 locus for late–onset Alzheimer disease provides genetic evidence for folate–pathway abnormalities. PLoS Genet. 6:e1001130. doi:10.1371/journal.pgen.1001130
Nettles, J. H., Li, H., Cornett, B., Krahm, J. M., Snyder, J. P., and Downing, K. H. (2004). The binding mode of epothilone A on alpha,beta–tubulin by electron crystallography. Science 305, 866–869. doi:10.1126/science.1099190
Nicotelli, M. I., Colombo, T., Rossi, C., Monardo, C., Stura, S., Zucchetti, M., et al. (2000). IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res. 60, 842–846.
Nogales, E., Wolf, S. G., and Downing, K. H. (1998). Structure of the alpha beta tubulin dimer by electron crystallography. Nature 391, 199–203. doi:10.1038/34465
Malishkevich, A., Marshall, G. A., Schultz, A. P., Sperling, R. A., Aharon–Peretz, J., and Gozes, I. (2016). Blood–Borne activity–dependent neuroprotective protein (ADNP) is correlated with premorbod intelligence, clinical stage, and Alzheimer’s disease biomarkers. J. Alzheimers Dis. 50, 249–260. doi:10.3233/JAD-150799

Nogales, E., Wolf, S. G., Khan, I. A., Ludue–a–a, R. F., and Downing, K. H. (1995). Structure of tubulin at 6.5 Å and location of the taxol–binding site. Nature 375, 424–427. doi: 10.1038/375424a0

Noori–Daloii, M. R., Kheirtofigh, M., Mahbod, P., Mohammadi, F., Astdaneh, A. N., Zarindast, M. R., et al. (2010). Alpha– and beta–synuclein mRNA expression in lymphocytes of schizophrenia patients. Genet. Test. Mol. Biomarkers 14, 728–729. doi: 10.1089/gtmb.2010.0050

Nyman, D. W., Campbell, K. J., Hersh, E., Long, K., Richardson, K., Trieu, V., et al. (2005). Phase I and pharmacokinetics trial of ABI–007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 23, 7785–7793. doi: 10.1200/jco.2004.01.6148

Ogawa, O., Lee, H. G., Zhu, X., Raina, A., Harris, P. L., Castellani, R. J., Ren, Y., Liu, W., Jiang, H., Jiang, Q., and Feng, J. (2005). Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Neurochem. 90, 1333–1344. doi: 10.1111/j.1471-4159.2005.05075.x

Sánchez–Calvo, G., Sharma, A., Balaguer, F. A., Barsoain, L., Rodríguez–Salarichs, J., Olieric, N., et al. (2017). Triazolopyrimidines are microtubule–stabilizing agents that bind the vinca inhibitor site of tubulin. Cell Chem. Biol. 24, 737.e6–750.e6. doi: 10.1016/j.chembiol.2017.05.016

Sandner, B., Puttganta, R., Motsch, M., Bradke, F., Ruschel, J., Blesch, A., et al. (2018). Systemic epothilone D improves hindlimb function after spinal cord contusion injury in rats. Exp. Neurol. 306, 250–259. doi: 10.1016/j.expneurol.2018.01.018

Sankaran, S., Crane, D. E., Palazzo, R. E., and Parvin, J. D. (2007). BRCA1 regulates gamma–tubulin binding to centrosomes. Cancer Biol. Ther. 6, 1853–1857. doi: 10.4161/cbt.6.12.5164

Schiff, P. B., and Horwitz, S. B. (1980). Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. U.S.A. 77, 1561–1565. doi: 10.1073/pnas.77.3.1561

Schinkel, A. H., Smit, J. I., van Tellingen, O., Beijnen, J. J., Wagenaar, E., van Deemter, L., et al. (1994). Disruption of the mouse mdrla P–glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 77, 491–502. doi: 10.1016/0092-8674(94)90212-7

Sessa, C., Perotti, A., Liado, A., Cresta, S., Capri, G., Voi, M., et al. (2007). Phase I clinical study of the novel epothilone B analogue BMS–310705 given on a weekly schedule. Ann. Oncol. 18, 1548–1553. doi: 10.1093/annonc/mdm198

Simón–Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., et al. (2009). Genome–wide association study reveals genetic risk underlying Parkinson’s disease. Nat. Genet. 41, 1308–1312. doi: 10.1038/ng.487

Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., et al. (2012). Weekly nab–paclitaxel in combination with carboplatin versus solvent–based paclitaxel plus carboplatin as first–line therapy in patients with advanced non–small–cell lung cancer, final results of a phase III trial. J. Clin. Oncol. 30, 2055–2062. doi: 10.1200/JCO.2011.39.5848

Spong, C. Y., Abebe, D. T., Gozes, I., Brennan, D. E., and Hill, J. M. (2001). Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J. Pharmacol. Exp. Ther. 297, 774–779.

Sragovich, S., Merenlender–Wagner, A., and Gozes, I. (2017). ADNP plays a key role in autophagy: from autism to schizophrenia and alzheimer’s disease. Bioessays 39,1700054. doi: 10.1002/bies.201700054

Steen, R. G., Hamer, R. M., and Lieberman, J. A. (2005). Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia, a systematic review and meta–analysis. Neupyschopharmacology 30, 1949–1962. doi: 10.1016/j.npp.2004.11.009

Stichel, C. C., Schoenebeck, R., Fuguet, M., Sieberth, J. B., Vezzani, A., and Knable, M. B. (2005). Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol. Psychiatry 57, 252–260. doi: 10.1016/j.biopsych.2004.10.019

Vaisburd, S., Shemer, Z., Yeheskel, A., Giladi, E., and Gozes, I. (2015). Risperidone and promoter in late onset Alzheimer's disease. Biol. Psychiatry 78, 1036–1040. doi: 10.1016/j.biopsych.2015.09.011

Van Cauwenberghe, C., Van Broeckhoven, C., and Sleegers, K. (2016). The genetic panel of human tumor xenografts. J. Clin. Oncol. 34, 347–352. doi: 10.1200/jco.2015.64.0028

Varidani et al. Repositioning Microtubule Drugs for Brain
Verdile, G., Gnjec, A., Miklóssy, J., Fonte, J., Veurink, G., Bates, K., et al. (2004). Protein markers for Alzheimer disease in the frontal cortex and cerebellum. Neurology 63, 1385–1392. doi: 10.1212/01.WNL.0000141848.45315.A6
Verhey, K. J., and Gaertig, J. (2007). The tubulin code. Cell Cycle 6, 2152–2160. doi: 10.4161/cc.6.17.4633
Volle, J., Brocard, J., Saoud, M., Gory–Faure, S., Brunelin, J., Andrieux, A., et al. Suau–Chagny (2013). Reduced expression of STOP/MAP6 in mice leads to cognitive deficits. Schizophr. Bull. 39, 969–978. doi: 10.1093/schbul/sbs113
Wang, B., Lv, L., Wang, Z., Jiang, Y., Lv, W., Liu, X., et al. (2015). Improved anti–glioblastoma efficacy by IL−13Ralpha2 mediated copolymer nanoparticles loaded with paclitaxel. Sci. Rep. 5:16589. doi: 10.1038/srep16589
Wang, H. Y., and Friedman, E. (1996). Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol. Psychiatry 40, 568–575. doi: 10.1016/0006-3223(95)00611-7
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., and McPhail, A. T. (1971). Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93, 2325–2327. doi: 10.1021/ja00738a045
Wijsman, E. M., Pankratz, N. D., Choi, Y., Rothstein, J. H., Faber, K. M., Cheng, R., et al. (2011). Genome–wide association of familial late–onset Alzheimer’s disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet. 7:e1001308. doi: 10.1371/journal.pgen.1001308
Witte, H., and Bradke, F. (2008). The role of the cytoskeleton during neuronal polarization. Curr. Opin. Neurobiol. 18, 479–487. doi: 10.1016/j.conb.2008.09.019
Yenjerla, M., LaPointe, N. E., Lopus, M., Cox, C., Jordan, M. A., Feinstein, S. C., et al. (2010). The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules. J. Alzheimers Dis. 19, 1377–1386. doi: 10.3233/JAD-101335
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T. C., et al. (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337–351. doi: 10.1016/j.neuron.2007.01.010
Yuan, P., Zhou, R., Wang, Y., Li, X., Li, J., Chen, G., et al. (2010). Altered levels of extracellular signal–regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J. Affect. Disord. 124, 164–169. doi: 10.1016/j.jad.2009.10.017
Zahavi, E. E., Maimon, R., and Perlson, E. (2017). Spatial–specific functions in retrograde neuronal signalling. Traffic 18, 415–424. doi: 10.1111/tra.12487
Zhang, B., Carroll, J., Trojanowski, J. Q., Yao, Y., Iba, M., Potuzak, J. S., et al. (2012). The microtubule–stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer–like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 32, 3601–3611. doi: 10.1523/JNEUROSCI.4922-11.2012
Zhang, C. C., Zhu, J. X., Wan, Y., Tan, L., Wang, H. F., and Yu, J. T. (2017). Meta–analysis of the association between variants in MAPT and neurodegenerative diseases. Oncotarget 8, 44994–45007. doi: 10.18632/oncotarget.16690
Zhu, X., Sun, Z., Lee, H. G., Siedlak, S. L., Perry, G., and Smith, M. A. (2003). Distribution, levels, and activation of MEK1 in Alzheimer’s disease. J. Neurochem. 86, 136–142. doi: 10.1046/j.1471-4159.2003.01820.x
Zong, Y., Wu, J., and Shen, K. (2017). Nanoparticle albumin–bound paclitaxel as neoadjuvant chemotherapy of breast cancer, a systematic review and meta–analysis. Oncotarget 8, 17360–17372. doi: 10.18632/oncotarget.14477

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Varidaki, Hong and Coffey. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.